bioMerieux (FR:BIM) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
bioMérieux has announced FDA 510(k) clearance for its VITEK® REVEAL™ antibiogram system, which provides rapid antibiotic sensitivity tests crucial for treating sepsis and combating antibiotic resistance. This innovative technology delivers results from positive blood cultures within approximately 5.5 to 6 hours, enabling same-day therapeutic decisions. The clearance marks a significant milestone for bioMérieux, enhancing its comprehensive solutions in the diagnostics market and supporting the proper use of antibiotics.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.